NCT06958679View on ClinicalTrials.gov

Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

January 30, 2027

Study Completion Date

June 30, 2028

Conditions
B-cell MalignanciesSolid Tumors
Interventions
DRUG

SYS6005

SYS6005 administered via IV infusion on , Day 1 of each 21-day cycle

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

All Listed Sponsors
lead

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY